



Iowa Medicaid
DUR Mental Health Work Group
Meeting Minutes February 22, 2008

Attendees**Work Group Members**

Bruce Alexander	Samuel Kuperman
Kevin Took	Terry Augspurger
Sara Schutte-Schenck	Rick Rinehart
Chris Okiishi	Chuck Wadle

Staff

Janalyn Phillips	Shelly Larson
Thomas Kline	

Guests

Heesung Yoon, PharmD Student	Sandy Pranger, IME
Chad Bissell, IME	Tim Clifford, GHS

Observers

Brian Fort, Bristol-Myers Squibb	Antonette Sampson, AstraZeneca
Kathy Bovid, Bristol-Myers Squibb	Anh La, AstraZeneca
Bryan Reichmuth, Lilly	Jay Siems, Lilly
Sean Stanga, Blank Children's Hospital	Karen Loihl, Iowa Psychiatric Society
Jennifer Ober, IME	Angela Erickson, IME
Cynthia Tracey, IME	Sally Nadolsky, IME
Nick Ford, IME	

Larson called the meeting to order at 8:30 a.m. at the Iowa Medicaid Enterprise. Commission members, guests, and observers were welcomed and introduced.

Larson provided an overview of the problems that developed for the pediatric and adolescent psychiatrists within the state when quantity limits were placed on October 28, 2007. Quantity limits on 9 drugs were rescinded on November 28, 2007.

The Mental Health Work Group (MHWG) discussed quantity limit edits for Abilify and Risperdal and their impact on the psychiatrists within the state. The MHWG agreed on the list of edits on the following page and these will be referred to the Iowa Medicaid Drug Utilization Review Commission for their approval. In addition, a letter regarding these edits will be forwarded to the Iowa Psychiatric Society for dissemination to its members for comments.

Drug Product	Quantity	Days Supply
Abilify 2mg	31	31
Abilify 10mg	31	31
Abilify 15mg	31	31
Abilify 20mg	31	31
Abilify 30mg	31	31
Risperdal 0.25mg	124	31
Risperdal 0.5mg	124	31
Risperdal 0.5mg M-TAB	124	31
Risperdal 1mg	124	31
Risperdal 1mg M-TAB	124	31
Risperdal 2mg	93	31
Risperdal 2mg M-TAB	93	31
Risperdal 3mg	62	31
Risperdal 3mg M-TAB	62	31
Risperdal 4mg	62	31
Risperdal 4mg M-TAB	62	31

The Quantity Limit Override Form was discussed. Bissell shared the step-by-step process for submitting the form and receiving a response from the Prior Authorization (PA) unit. While the overrides are Prospective Drug Utilization Review (ProDUR) edits, it is the PA unit's intent to process the Quantity Limit Override Forms on the same timely basis as PA requests.

The meeting was adjourned at 9:45 a.m.

The next meeting will be held at 8:30 a.m. on Friday, April 11, 2008 at the Iowa Medicaid Enterprise.